Advertisement
Screener

ImmuCell Corporation (ICCC) Excess Tax Benefit from Share-based Compensation, Financing Activities

2.8 / 5 stars · 68/120 Roast Me

ImmuCell Corporation Excess Tax Benefit from Share-based Compensation, Financing Activities

ImmuCell Corporation (ICCC) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $78.43 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-15.

Discontinued › Notes › Compensation Related Costs

us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2021-11-15

  • ImmuCell Corporation excess tax benefit from share-based compensation, financing activities for the quarter ending 2021-09-30 was $78.43K.
  • ImmuCell Corporation excess tax benefit from share-based compensation, financing activities for the quarter ending 2021-06-30 was $102.44K.
Period endExcess Tax Benefit from Share-based Compensation, Financing Activities 3 monthExcess Tax Benefit from Share-based Compensation, Financing Activities 6 month
2021-09-30$78.43K
10-Q · filed 2021-11-15
$180.87K
derived: sum of 2 quarters · filed 2021-11-15
2021-06-30$102.44K
10-Q · filed 2021-08-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
VOLITIONRX LTD (VNRX)$0.003B-0.64
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92